Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Ahmad-Samer Al-Homsi, Sebastien Anguille, Dries Deeren, Taiga Nishihori, Nathalie Meuleman, Maher Abdul-Hay, Gareth J. Morgan, Jason Brayer, Nathalie Braun, Caroline Lonez, Marie-Sophie Dheur, Erik Alcantar-Orozco, David Gilham, Anne Flament, Frédéric F. Lehmann

Blood (2021) 138 (Supplement 1): 2817.

https://doi.org/10.1182/blood-2021-147738

Published: 2021

Journal Articles

TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Leona Holmberg, Nathalie Meuleman, Philippa Graham, Olivier De Henau, Gregory Driessens, Yvonne McGrath, Joanne Lager, Geoffrey R Hill

Blood (2021) 138 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2021-152395

Published: 2021

Journal Articles

Real-World Outcomes for Standard-of-Care Treatments in Patients with Relapsed/Refractory Multiple Myeloma

Michel Delforge, Marie-Christiane Vekemans, Sébastien Anguille, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Vande Broek, Danielle Strens, Sandra Van Hoorenbeeck, Evelien J Moorkens, Joris Diels, Francesca Ghilotti, Sander Dalhuisen, Sophie Vandervennet

Blood (2021) 138 (Supplement 1): 4075.

https://doi.org/10.1182/blood-2021-146250

Published: 2021

Journal Articles

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

A. Samer Al-Homsi, MD, Sebastien Anguille, MD, Jason Brayer, PhDMD, Dries Deeren, MD PhD, Nathalie Meuleman, PhD MD, Gareth Morgan, MDPhDFRCP, Taiga Nishihori, MD, Panagiota A. Sotiropoulou, PhD, Laure Twyffels, PhD, Jennifer Bolsee, PhD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD, Frédéric F. Lehmann, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139516

Published: 2020

Journal Articles

A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination As Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma

Fulvio Massaro, MD, Nathalie Meuleman, PhD MD, Dominique Bron, MDPhD, Marie Maerevoet, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-137399

Published: 2020

Journal Articles

Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03)

Arthur Bobin, Guillemette Fouquet, Alain Duhamel, PU/PH, Salomon Manier, MD PhD, Lionel Karlin, MD, Brigitte Kolb, MD, Mourad Tiab, MD, Carla Araujo, MD, Nathalie Meuleman, PhD MD, Jean Valère Malfuson, MD, Pascal Bourquard, MD, Pascal Lenain, MD, Arnaud Jaccard, MD PhD, Karim Belhadj, MD, Michel Attal, MD PhD, Philippe Moreau, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD

Blood (2019) 134 (Supplement_1): 3190.

https://doi.org/10.1182/blood-2019-131793

Published: 2019

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

Blood (2018) 132 (Supplement 1): 598.

https://doi.org/10.1182/blood-2018-99-116663

Published: 2018

Journal Articles

Light Chain Escape in Multiple Myeloma

Thomas Dejoie, MD, Guillemette Fouquet, Cyrille Hulin, Murielle Roussel, Benjamin Hebraud, Lionel Karlin, MD, Brigitte Kolb, MD, Carla Araujo, MD, Nathalie Meuleman, PhD MD, Mourad Tiab, MD, Jean Valère Malfuson, MD, Pascal Bourquard, MD, Pascal Lenain, MD, Arnaud Jaccard, MD PhD, Karim Belhadj, Gérard Lepeu, MD, Marie Lorraine Chretien, MD, Denis Caillot, Jean Fontan, MD, Philippe Rodon, MD, Anna Schmitt, Laurent Voillat, MD, Sophie Cereja, MD, Brigitte Pegourie, MD, Frederique Kuhnowski, MD, Sophie Rigaudeau, MD, Olivier Decaux, MD, Catherine Humbrecht-Kraut, MD, Jamilé Frayfer, MD, Laurent Garderet, Damien Roos-Weil, MD, Jean Claude Eisenmann, MD, Veronique Dorvaux, MD, Eric G. Voog, MD, Claire Mathiot, MD, Jean-Paul Fermand, MD, Thierry Facon, Hervé Avet-Loiseau, MD PhD, Jean Luc Harousseau, MD, Philippe Moreau, Michel Attal, MD PhD, Xavier Leleu, MD PhD

Blood (2018) 132 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2018-99-112396

Published: 2018

Journal Articles

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1886.

https://doi.org/10.1182/blood.V130.Suppl_1.1886.1886

Published: 2017

Journal Articles

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Blood (2016) 128 (25): 2941–2948.

https://doi.org/10.1182/blood-2016-07-726778

Published: 2016

Journal Articles

Early Discontinuation of Lenalidomide in Patients with Relapsing or Refractory Multiple Myeloma: Predictive Factors for Stopping in the Real Life

Aureliano Pistone, MD, Marie Maerevoet, MD, Sebastian Wittnebel, MD PhD, Marie Vercruyssen, Chloé Spilleboudt, MD, Sarah Buntinx, MD, Dominique Bron, MD PhD, Nathalie Meuleman, MD PhD

Blood (2016) 128 (22): 4504.

https://doi.org/10.1182/blood.V128.22.4504.4504

Published: 2016

Journal Articles

Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma

Blood (2016) 128 (22): 993.

https://doi.org/10.1182/blood.V128.22.993.993

Published: 2016

Journal Articles

IFM2012-03

Blood (2016) 128 (22): 2128.

https://doi.org/10.1182/blood.V128.22.2128.2128

Published: 2016

Journal Articles

Prediction of Poor Outcome in Older Patients Receiving Chemotherapy for Malignant Lymphoma: A New Frailty Scoring

Stephanie Dubruille, PhD, Cindy Kenis, PhD, Yves Libert, PhD, Michel Delforge, MD PhD, Catherine Choffray, Myriam Roos, Aurélie Collard, Nathalie Meuleman, MD PhD, Marie Maerevoet, MD, Darius Razavi, MD PhD, Hans Wildiers, MD PhD, Dominique Bron, MD PhD

Blood (2016) 128 (22): 2353.

https://doi.org/10.1182/blood.V128.22.2353.2353

Published: 2016

Journal Articles

A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

Thierry Facon, Cyrille Hulin, Meletios A. Dimopoulos, Andrew Belch, Nathalie Meuleman, Mohamad Mohty, Wen-Ming Chen, Kihyun Kim, Elena Zamagni, Paula Rodriguez-Otero, MD PhD, William Renwick, Christian Rose, Adrian Tempescul, Antonio Palumbo, Shien Guo, Michael Sturniolo, Annette Ervin-Haynes, Jean-Paul Fermand

Blood (2015) 126 (23): 4239.

https://doi.org/10.1182/blood.V126.23.4239.4239

Published: 2015

Journal Articles

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Blood (2015) 126 (23): 3028.

https://doi.org/10.1182/blood.V126.23.3028.3028

Published: 2015

Journal Articles

Prognostic Value of Neuro-Psychological and Biological Factors in Clinically Fit Older Patients with Hematological Malignancies

Stéphanie Dubruille, M.A., Yves Libert, PhD, Marie Maerevoet, MD, Myriam Roos, Aurélie Collard, Sandrine Vandenbossche, M.A., Nathalie Meuleman, MD PhD, Darius Razavi, MD PhD, Dominique Bron, MD PhD

Blood (2014) 124 (21): 2630.

https://doi.org/10.1182/blood.V124.21.2630.2630

Published: 2014

Journal Articles

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

Blood (2013) 121 (11): 1968–1975.

https://doi.org/10.1182/blood-2012-09-452375

Published: 2013

Includes: Supplemental data

Journal Articles

International Observational Study On Bortezomib (VELCADE) in Relapsed Multiple Myeloma: Preliminary Efficacy and Quality of Life (QoL) Results From the Belgian Population.

Michel Delforge, MD, PhD, Hadewijch De Samblanx, Hilde Demuynck, Greet Bries, Philippe Mineur, Nathalie Meuleman, Fritz Offner, Chantal Doyen, Walter Feremans, Ann Van de Velde, Christophe Ravoet, Isabelle Vande Broek, Jan Van Droogenbroeck, Gabry Kuijten-Celzo, Joris Diels, Rita Ganguly, Ravinder Dhawan

Blood (2009) 114 (22): 4523.

https://doi.org/10.1182/blood.V114.22.4523.4523

Published: 2009

NARROW

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma

Real-World Outcomes for Standard-of-Care Treatments in Patients with Relapsed/Refractory Multiple Myeloma

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination As Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma

Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03)

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

Light Chain Escape in Multiple Myeloma

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Early Discontinuation of Lenalidomide in Patients with Relapsing or Refractory Multiple Myeloma: Predictive Factors for Stopping in the Real Life

Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma

IFM2012-03

Prediction of Poor Outcome in Older Patients Receiving Chemotherapy for Malignant Lymphoma: A New Frailty Scoring

A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Prognostic Value of Neuro-Psychological and Biological Factors in Clinically Fit Older Patients with Hematological Malignancies

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

International Observational Study On Bortezomib (VELCADE) in Relapsed Multiple Myeloma: Preliminary Efficacy and Quality of Life (QoL) Results From the Belgian Population.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only